JMP Securities Reiterates Market Outperform on Taysha Gene Therapies, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $5 price target, indicating a positive outlook on the company's stock.
March 20, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Silvan Tuerkcan reiterated a Market Outperform rating on Taysha Gene Therapies with a $5 price target, suggesting a positive future performance.
The reiteration of a Market Outperform rating and the maintenance of a $5 price target by JMP Securities analyst Silvan Tuerkcan for Taysha Gene Therapies (TSHA) is a strong positive signal to investors. This suggests confidence in the company's future performance and potential for stock price appreciation, likely leading to a positive short-term impact on TSHA's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100